

FORM 9

NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES
(or securities convertible or exchangeable into listed securities)

Name of Listed Issuer: BioVaxys Technology Corp. (the "Issuer") Symbol(s): BIOV

Date: May 3, 2024 Is this an updating or amending Notice: ☒ Yes ☐ No

If yes provide date(s) of prior Notices: March 21, 2024

Issued and Outstanding Securities of Issuer Prior to Issuance: 210,813,161 Shares

Pricing

Date of news release announcing proposed issuance: Not applicable or

Date of confidential request for price protection: March 8, 2024

Closing Market Price on Day Preceding the news release: Not applicable or

Day preceding request for price protection: \$0.07

Closing

Number of securities to be issued: **FIRST TRANCHE: 5,126,574 units of the Issuer (the "Units" and each, a "Unit") at a price of \$0.065 per Unit for aggregate gross proceeds of \$333,227.31, whereby each Unit consists of one (1) common share in the capital of the Issuer (each, a "Share") and one (1) Share purchase warrant of the Issuer (each a "Warrant"). Each Warrant entitles the holder thereof to acquire one additional Share (each, a "Warrant Share") at a price of \$0.15 per Warrant Share for a period of 24 months from the date of issuance.**

Issued and outstanding securities following issuance: 215,939,735 Shares

Instructions:

1. For private placements (including debt settlement), complete tables 1A and 1B in Part 1 of this form.
2. Complete Table 1A – Summary for all purchasers, excluding those identified in Item 8.
3. Complete Table 1B – Related Persons only for Related Persons
4. If shares are being issued in connection with an acquisition (either as consideration or to raise funds for a cash acquisition) please proceed to Part 2 of this form.
5. An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10 – Notice of Proposed Transaction
6. Post the completed Form 9 to the CSE website in accordance with *Policy 6 – Distributions*. In addition, the completed form must be delivered to listings@thecse.com with an appendix that includes the information in Table 1B for ALL placees.

Part 1. Private Placement – FIRST TRANCHE

Table 1A – Summary

Each jurisdiction in which purchasers reside	Number of Purchasers	Price per Security	Total dollar value (CDN\$) raised in the jurisdiction
British Columbia	1	\$0.065/per Unit	\$149,999.98
Ontario	7	\$0.065/per Unit	\$118,227.33
Isle Of Man	1	\$0.065/per Unit	\$65,000
Total number of purchasers:	9		
Total dollar value of distribution in all jurisdictions:			\$333,227.31

Table 1B – Related Persons

Full Name & Municipality of Residence of Placee	Number of Securities Purchased or to be Purchased	Purchase price per Security (CDN\$)	Conversion Price (if Applicable) (CDN\$)	Prospectus Exemption	Total Securities Previously Owned, Controlled or Directed	Payment Date ⁽¹⁾	Describe Relationship to Issuer ⁽²⁾
Not applicable							

¹An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10.

1. Total amount of funds to be raised: **\$333,227.31**
2. Provide full details of the use of the proceeds. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material. **The Issuer intends to use the proceeds raised from this first tranche for working capital purposes to enable the Issuer to advance its business plans in regards to its recent acquisition of the entire portfolio of discovery, preclinical and clinical development stage assets in oncology, infectious disease, antigen desensitization, and other immunological fields based on the DPX™ immune educating platform technology, developed by the former Canadian biotechnology company, IMV Inc., Immunovaccine Technologies Inc., and IMV USA.**
3. Provide particulars of any proceeds which are to be paid to Related Persons of the Issuer: **Not applicable**
4. If securities are issued in forgiveness of indebtedness, provide details of the debt agreement(s) or and the agreement to exchange the debt for securities. **Not applicable**
5. Description of securities to be issued:
 - (a) Class: **Shares**
 - (b) Number: **5,126,574 Shares**
 - (c) Price per security: **\$0.065 per Unit**

**FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF
LISTED SECURITIES**

- (d) Voting rights: **Each Share entitles the holder to one vote.**
6. Provide the following information if warrants, (options) or other convertible securities are to be issued:
- (a) Number: **5,126,574 Warrants**
- (b) Number of securities eligible to be purchased on exercise of warrants (or options): **5,126,574 Warrant Shares**
- (c) Exercise price: **\$0.15 per Warrant Share**
- (d) Expiry date: **24 months from date of issuance**
7. Provide the following information if debt securities are to be issued:
- (a) Aggregate principal amount: **Not applicable**
- (b) Maturity date: **Not applicable**
- (c) Interest rate: **Not applicable**
- (d) Conversion terms: **Not applicable**
- (e) Default provisions: **Not applicable**
8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the placement (including warrants, options, etc.):
- (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the placement (name, and if a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): **The Issuer has paid pay finder's fees in connection with certain subscriptions to two finders, being (i) Canaccord Genuity Corp., 2200 - 609 Granville Street, Vancouver, BC V7Y 1H2; and (ii) Research Capital Corporation, 1920 - 1075 West Georgia Street, Vancouver, BC V6E 3C9**
- (b) Cash: **an aggregate of \$6,500.00 in finder's fees comprising (i) \$3,900.00 to Canaccord Genuity Corp.; and (ii) \$2,600.00 to Research Capital Corporation**
- (c) Securities: **60,000 Finder's Warrants issued to Canaccord Genuity Corp.**
- (d) Other: **Not applicable**
- (e) Expiry date of any options, warrants, etc. **May 3, 2026**
- (f) Exercise price of any options, warrants etc. **\$0.15 per Warrant Share**

9. State whether the sales agent, broker, dealer or other person receiving compensation in connection with the placement is Related Person or has any other relationship with the Issuer and provide details of the relationship: **Not applicable**
10. Describe any unusual particulars of the transaction (i.e. tax “flow through” shares, etc.). **Not applicable.**
11. State whether the private placement will result in a change of control or if the issuance will materially affect control of the Issuer. **The private placement will not result in a change of control nor materially affect control of the Issuer.**
12. Where there is a change in the control of the Issuer resulting from the issuance of the private placement shares, indicate the names of the new controlling shareholders. **Not applicable**
13. Each purchaser has been advised of the applicable securities legislation restricted or seasoning period. All certificates for securities issued which are subject to a hold period bear the appropriate legend restricting their transfer until the expiry of the applicable hold period required by National Instrument 45-102 Resale of Securities.

Part 2. Acquisition – NOT APPLICABLE

1. Provide details of the assets to be acquired by the Issuer (including the location of the assets, if applicable). The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material: **Not applicable**
2. Provide details of the acquisition including the date, parties to and type of agreement (eg: sale, option, license etc.) and relationship to the Issuer. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the acquisition without reference to any other material: **Not applicable**
3. Provide the following information in relation to the total consideration for the acquisition (including details of all cash, securities or other consideration) and any required work commitments:
- (a) Total aggregate consideration in Canadian dollars: **Not applicable**
 - (b) Cash: **Not applicable**
 - (c) Securities (including options, warrants etc.) and dollar value: **Not applicable**
 - (d) Other: **Not applicable**
 - (e) Expiry date of options, warrants, etc. if any: **Not applicable**
 - (f) Exercise price of options, warrants, etc. if any: **Not applicable**
 - (g) Work commitments: **Not applicable**
4. State how the purchase or sale price was determined (e.g. arm’s-length negotiation, independent committee of the Board, third party valuation etc). **Not applicable**

5. Provide details of any appraisal or valuation of the subject of the acquisition known to management of the Issuer: **Not applicable**
6. The names of parties receiving securities of the Issuer pursuant to the acquisition and the number of securities to be issued are described as follows:

Name of Party (If not an individual, name all insiders of the Party)	Number and Type of Securities to be Issued	Dollar value per Security (CDN\$)	Conversion price (if applicable)	Prospectus Exemption	Total Securities, Previously Owned, Controlled or Directed by Party	Describe relationship to Issuer ⁽¹⁾
Not applicable						

(1) Indicate if Related Person

7. Details of the steps taken by the Issuer to ensure that the vendor has good title to the assets being acquired: **Not applicable**
8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the acquisition (including warrants, options, etc.):
- (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the acquisition (name, and if a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): **Not applicable**
 - (b) Cash: **Not applicable**
 - (c) Securities: **Not applicable**
 - (d) Other: **Not applicable**
 - (e) Expiry date of any options, warrants, etc.: **Not applicable**
 - (f) Exercise price of any options, warrants, etc.: **Not applicable**
9. State whether the sales agent, broker or other person receiving compensation in connection with the acquisition is a Related Person or has any other relationship with the Issuer and provide details of the relationship. **Not applicable**
10. If applicable, indicate whether the acquisition is the acquisition of an interest in property contiguous to or otherwise related to any other asset acquired in the last 12 months. **Not applicable**

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance on behalf of the Issuer.
2. As of the date hereof there is not material information concerning the Issuer which has not been publicly disclosed.
3. the Issuer has obtained the express written consent of each applicable individual to:
 - (a) the disclosure of their information to the Exchange pursuant to this Form or otherwise pursuant to this filing; and
 - (b) the collection, use and disclosure of their information by the Exchange in the manner and for the purposes described in Appendix A or as otherwise identified by the Exchange, from time to time
4. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CSE Policy 1).
5. All of the information in this Form 9 Notice of Issuance of Securities is true.

Dated May 3, 2024

James Passin
Name of Director or Senior Officer

/s/ James Passin
Signature

Chief Executive Officer and Director
Official Capacity

Appendix A

PERSONAL INFORMATION COLLECTION POLICY REGARDING FORM 9

The Canadian Securities Exchange and its subsidiaries, affiliates, regulators and agents (collectively, “CSE or the “Exchange”) collect and use the information (which may include personal or other information) which has been provided in Form 9 for the following purposes:

- To determine whether an individual is suitable to be associated with a Listed Issuer;
- To determine whether an issuer is suitable for listing;
- To determine whether allowing an issuer to be listed or allowing an individual to be associated with a Listed Issuer could give rise to investor protection concerns or could bring the Exchange into disrepute;
- To conduct enforcement proceedings;
- To ensure compliance with Exchange Requirements and applicable securities legislation; and
- To fulfil the Exchange’s obligation to regulate its marketplace.

The CSE also collects information, including personal information, from other sources, including but not limited to securities regulatory authorities, law enforcement and self-regulatory authorities, regulation service providers and their subsidiaries, affiliates, regulators and agents. The Exchange may disclose personal information to these entities or otherwise as provided by law and they may use it for their own investigations.

The Exchange may use third parties to process information or provide other administrative services. Any third party will be obliged to adhere to the security and confidentiality provisions set out in this policy.

All personal information provided to or collected by or on behalf of The Exchange and that is retained by The Exchange is kept in a secure environment. Only those employees who need to know the information for the purposes listed above are permitted access to the information or any summary thereof. Employees are instructed to keep the information confidential at all times.

Information about you that is retained by the Exchange and that you have identified as inaccurate or obsolete will be corrected or removed.

If you wish to consult your file or have any questions about this policy or our practices, please write the Chief Privacy Officer, Canadian Securities Exchange, 220 Bay Street – 9th Floor, Toronto, ON, M5J 2W4.